Checking treatment for multiple myeloma after MRD becomes negative
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed multiple myeloma and are a good candidate for high-dose treatment and stem cell transplant (ASCT).
- You are older than 18 and younger than 75 when you sign consent.
- You must have measurable myeloma in the blood or abnormal light chain blood tests that show disease is present.
- Your health and daily function are good (ECOG 0–2), or ECOG 3 only if it is caused by myeloma.
- You must be able and willing to follow the study visit schedule and procedures.
- If you can become pregnant (or have a partner who can): you must use very effective birth control during the study and for at least 28 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This early-phase study looks at whether it’s safe to stop the usual “maintenance” medicine after a strong response in multiple myeloma. It aims to see if stopping treatment for people with very low remaining disease reduces drug exposure without allowing relapse too soon.
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.